Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medacta Group SA ( (CH:MOVE) ) has issued an announcement.
Medacta Group SA reported a significant revenue growth of 19.8% in constant currency for the first half of 2025, reaching Euro 344.1 million. This growth was driven by substantial performance across all business lines and geographic markets, with notable increases in the Asia Pacific and North America regions. The company also upgraded its full-year and mid-term guidance, reflecting its strong market position and successful integration of Parcus Medical, which contributed to the revenue increase. Medacta’s focus on innovative solutions and medical education continues to bolster its industry standing and offers promising implications for stakeholders.
The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF160.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.
More about Medacta Group SA
Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 70 countries.
Average Trading Volume: 8,461
Technical Sentiment Signal: Buy
Current Market Cap: CHF2.8B
For a thorough assessment of MOVE stock, go to TipRanks’ Stock Analysis page.